MDR Namsa Slides

MEDICAL RESEARCH ORGANIZATION
The New European MDR- Harmonization Effort with International Regulatory Requirements
for Medical Devices
Stephan Buttron, | Principal Medical Research Manager Regulatory Affairs NAMSA |
March 15 , 2016
NAMSA The New European MDR| Confidential | 1
Europe

TOPICS
Key • Introduction to MDR

Webinar • New Key Decision Makers
&
Discussion • Review of Major Changes
Points • Implementation and Transition Timelines
• Key Impact
• Implementation Steps

MDR – Introduction
Timelines
3 Year Transition 5 Year MDD

Period Cert Grace
Q1/ 2017 Period
Adoption of
MDR
Q2/ 2017 2024

2020
Entry into Force End of transition Last possible
Date of Application granted MDD
certificate expires
Notified Bodies Re-
accreditation Process

MDD vs. MDR
MDD MDR
• 60 Pages (MDD only) • 352 Pages (MDD + AIMD)
• 23 Articles • 10 Chapters incl. 97 Articles
• 12 Annexes • 17 Annexes
D=Directive: Legislation that R=Regulation: Mandatory

sets out rules and must be Jurisdiction that is directly
transposed into national law to applicable and enforceable in all
be effective EU Member States.
5
Key Objectives of the MDR
• Fundamental revision of existing MDD and AIMD

• Reinforce key elements of the existing regulatory approach, such as:
- Patient’s Health and Safety
- Scientific Clinical Evaluation and Clinical Data Requirements
- Post-Market Surveillance and Post-Market Clinical Performance
- Role and Supervision of Notified Bodies
- Consistency and Transparency in Conformity Assessment Procedures
• Introduce provisions for transparency and traceability regarding devices to
improve health and safety.

Key Objectives of the MDR
• Promote the global convergence of regulations.

• Set high standards for quality, safety and clinical performance
for medical devices including IVDs.
• Regulate devices without a medical purpose
• Set out the regulatory obligations of economic operators
Establish a robust, transparent, predictable and sustainable

regulatory framework for Medical Devices including IVDs in
Europe

New Key Decision-Making Players
• European Commission (EC)

• EU Competent Authorities (NCA)
• Medical Device Coordination Group (MDCG)1
• Notified Bodies (NB)
• (Special) Notified Bodies (NB)2
Note: 1 is a new player. 2 is an existing player with special accreditation
based on very stringent competency and organizational requirements.

Scope of MDR:
Devices with Medical Purpose
Article 2(1) ‘medical device’ means any instrument, apparatus, appliance,
software, implant, reagent, material or other article, intended by the
manufacturer to be used, alone or in combination, for human beings for one
or more of the specific medical purposes of:
• Diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of
disease,
• Diagnosis, monitoring, treatment, alleviation of or compensation for an injury or
disability,
• Investigation, replacement or modification of the anatomy or of an physiological or
pathological process or state,
• Providing information by means of in vitro examination of specimens derived from
the human body, including organ, blood and tissue donations,
And which does not achieve its principal intended action by pharmacological,
immunological or metabolic means, in or on the human body, but which may be assisted
in its function by such means.
Products specifically intended for the cleaning, disinfection or sterilization of medical
devices and devices for the purpose of control or support or conception shall be
considered medical devices.

Scope of MDR:
Devices without Medical Purpose
Preambel (12): Certain groups of products for which the manufacturer
claims only an aesthetic or another non-medical purpose but which are
similar to medical devices in terms of functioning and risks profile
should be covered by this Regulation (common specifications adopted).
Article 1(2): This regulation shall also apply to the groups of products
without an intended medical purpose that are listed in Annex XVI as
from the date of application of common specifications adopted pursuant to
Article 7…taking into account the state of the art, and in particular existing
standards for analogous devices with a medical purpose, based on a
similar technology.

Software- New Classification Rules
• Software is considered an active medical device [Article 2

Definitions, Clause (4)]
• Classified into classes I, IIa, IIb or III depending on the
intended use of the software and a risk profile:
• Decision Software: intended to provide information which
is used to take decisions with diagnosis or therapeutic
purposes.

If decisions have an impact that may directly or

indirectly cause:
• Class III- the death or an irreversible deterioration of

the state of health
• Class IIb- a serious deterioration of the state of health
or a surgical intervention
• Class IIa- otherwise

“Monitoring Software”:
• Class IIa: if intended to monitor physiological
processes:
• Class IIb: If intended for monitoring of vital
physiological parameters, where the nature of
variations is such that it could result in immediate
danger to the patient
• All other software is in Class I.

Software- Other Important Changes
• Introduced concept of Interoperability to devices including

software:
- the ability to exchange information and use the information that
has been exchanged for correct execution of specified function
without changing the content of the data, and/or
- communicate with each other, and/or
- work together as intended.
• Interoperability (and compatibility) must be reliable and safe
• Software change evaluation: new or modified algorithms,
database structures, operating platform, architecture or new user
interfaces or new channels for interoperability

MDR – Major Changes
Pre-Approval
• Four (4) Device Classifications: no more AIMD -> Class
III, Class IIb;; Class IIa;; Class
• New “clinical evaluation consultation procedure ” for all
class III and certain Class IIb devices .
• Mandatory clinical investigations for implantable devices
and Class III devices with few exceptions
• Common [Technical] Specifications (CS) to be devised
and followed for product groups.

MDR – Major Changes
Post-Approval
• Centralized Post Market Surveillance System (PMS) for
all devices classes.
• New and different reporting requirements

- PMSR Post Market Surveillance Report,
- PSUR Periodic Safety Update Report,
- SSCP Summary of Safety & Clinical Performance,
- PMCFR Post Market Clinical Follow Up Reports

Post-Market Surveillance, Vigilance and Market Surveillance
[Chapter VII]
Post-Market Surveillance
Explicit provisions on manufacturers’ responsibilities for the follow-up of the
quality, performance and safety of devices placed on the market:
- Post-Market Surveillance (PMS) Plan.

- Periodic Safety Update Report (PSUR)
• Class IIa (every 2 years) and IIb/III (annually) incl. the
volume of sales.
• For class III, Notified Body Review and Assessment.
• For class III, PSUR and NB Assessment posted within an
Electronic Database available to all National Competent
Authorities.

MDR – Changes
New centralized databases (EUDAMED):

- Conformity Assessment;; Vigilance (incidents and recalls);;
- Universal Device Identifier (UDI);;
- Device Registration;;
- Surveillance Reports;;
- Clinical Investigations;;
- Notified Bodies

[Chapter VII]
Increase powers of the Competent Authorities to ensure swift

and effective response to safety problems:
• CA may intervene in a manufacturer’s investigation or initiate an
independent investigation
• Following risks identified and the analysis of vigilance data, CA may
request manufacturer or the EC Authorized Representative to take
“necessary” field corrective actions
• New high-level of involvement of Competent Authorities and Notified
Bodies in any filed actions (alias recalls).]
Reporting of serious incidents within 15 days and Field Safety
Corrective Actions through an Electronic System

[Chapter VII]
- Cooperation between CA and European Medicines

Agency (EMA) for drug-device combination products
in case of Serious incidents or FSCA.
- Explicitly advises manufacturers “not to play down the
level of risk” in field safety notices.
- Mandatory review of Field Safety Notice (FSN) by CA.
- FSN entered into an Electronic System accessible to the
Public.

Quality Management System Requirements
Greater emphasis and detailed QMS responsibilities.

Legal Manufacturer
• Person responsible for Regulatory Compliance- a new provision
with explicitly defined:
• Qualification requirements- specific education, training and
experience
• Responsibilities- conformity of device verified before product release,
technical documentation are kept up-to-date, PMS obligations are
complied with, etc.
• Provision for ability to make decision (“shall suffer no disadvantage
in relation to the proper fulfillment of his duties …”)

UDI: Identification and Traceability of Devices
• UDI system (Unique Device Identification System) to enable global

device traceability
• EUDAMED: Establishment of an electronic system on UDI
• EUDAMED Implementation by the EU Commission (the later date):
- MDR Entry Into Force (EIF) + three (3) years (alias Date of
Application of the MDR), or
- Six (6) months after publication of the EUDAMED Implementation
Notice

UDI: Identification and Traceability of Devices [Chapter III]
• UDI system (Unique Device Identification System) to enable

global device traceability

• UDI system (Unique Device Identification System) to enable

global device traceability

UDI Implementation Timelines by Manufacturers:

- UDI carrier must be affixed to devices by the following time
limits after the Date of Applications of the Regulation:
• Implantable and Class III devices - Within 1 year
• Class IIa and IIb devices - Within 3 years
• Class I - Within 5 years

Clinical Evaluation and Clinical Investigations [Chapter VI]
New understanding of Clinical Evaluation:

A systematic and planned process to continuously
generate, collect, analyze and assess the clinical data to
verify the safety and performance of a device when used as
intended by the manufacturer.
• Clinical Evaluation Report is required for all classes of
devices and throughout the product life cycle process.

Stringent new requirements for demonstrating equivalency:
þ Only be based on a single CE-Marked Device
þ Equivalency based on all three (3) design characteristics
þ No clinically significant difference in performance and safety
þ All differences need to be disclosed and critically evaluated
þ Notified Bodies may challenge equivalent device selection

as well as equivalent safety and performance data
Demonstration of Equivalency must be endorsed by the Notified

Body.

Clinical Evaluation shall be based on the following principals:

- Critical evaluation of all relevant scientific literature
- Critical evaluation of the results of all available clinical
investigations
- Consideration of currently available alternative treatment
options for claimed intended use.
- Optional consulting with an expert panel prior to its clinical
evaluation or clinical investigation as well as mandatory clinical
investigations for Class III and Implant Devices.
- Notified Body to review and approve advertising and promotional
materials (Ad& Promo Review)1
Note 1: Refer to guidance MEDDEV 2.7.1 Rev. 4 of June 2016

Transitional provisions [Article 120]
Clinical investigations which have started to be conducted

in accordance with Article 10 of Directive 90/385/EEC or Article
15 of Directive 93/42/EEC prior to the application of this
Regulation may continue to be conducted… [Clause 11]
NAMSA The New European MDR| Confidential | 29 29

MDR Implementation Timeline
The MDR is not approved by the European Council and European
Parliament yet.
• Entry into Force (EIF) = Publication date in the OJ + 20 day (Article 123)
• Date of Application (DOA) means a date when the application of the
new MDR Regulation becomes mandatory.
• Date of Application = Entry Into Force (Q2/2017) plus 3 years = 2020

MDD/AIMD Certificates Issued Prior to Entry into Force

Entry Into End of
Force Transition
2017 2021
Certificate issed Certificate valid for max. 5 years

until 2021
By way of derogation from Directives 90/385/EEC and 93/42/EEC, devices

which comply with this Regulation may be placed on the market before
its date of application.

MDD/AIMD Certificates Issued after Entry Into Force

Entry Into Date of End of
Force (EIF) Application (DOA) Transition
2017 2020 2024
Certificate issued Certificate valid for max. 5 years
Devices which were lawfully placed on the market pursuant to Directives
90/385/EEC and 93/42/EEC prior to the date referred to in Article 97(2)
(=DOA) may continue to be made available until 5 years after that date.

General Obligations of Economic Operators
‘Economic operators’ means:

- Legal Manufacturer
- EC Authorized Representative
- Importer
- Distributor
- Person who puts together [refer to Article 22 [1] or sterilizes
[refer to Article 22[3] system or procedure packs

General Obligations of Economic Operators
EC Authorized Representative [Articles 10 and 11]

- Verify that the EU declaration of conformity and technical
documentation have been drawn up and an appropriate conformity
assessment procedure has been carried out by the manufacturer.
- EU Representative keeps a permanent copy of :
• Technical documentation
• EU Declaration of Conformity
• Relevant certificates including any amendments and supplements
- Comply with the any required registration obligations and verify that the
manufacturer has complied with the registration obligations
- If requested, provide competent authority with all the information
and documentation necessary to demonstrate the conformity of a
device in an official Union language determined by the Member State
concerned.

General Obligations of Economic Operators: Importers
[Article 13]
More responsibilities for Importers:

Specific verification responsibilities include:
- CE marked devices and valid declaration of conformity
- Identification of legal manufacturer and designated EU Authorized
Representative in accordance with Article 9
- Labeling in accordance with this Regulation and accompanied by the
required instructions for use;;
- Unique Device Identification - assigned and registered
• Obligation to cooperate with the legal manufacturer, AR and Competent
Authorities to ensure the necessary corrective action to bring device into
conformity, or to result in its withdrawal or recall.

General Obligations for Economic Operators
Verify compliance with requirements
Supplier Manufacturer Importer Distributor
End
Post market surveillance and vigilance User
Regulatory compliance of device

Key Changes for Notified Bodies
• No grandfathering of Notified Bodies!

• Current NB designations will expire with the DOA of the
MDR.
• All Notified Body Applicants for MDR Accreditation must
go through the Re-Designation Process [Chapter IV
Notified Body] .

Key Changes for Notified Bodies
EU Commission shall within six (6) months of EIF of MDR draw up a list of
codes and corresponding types of devices to describe the scope of the
designation of Notified Bodies.
Notified Bodies must satisfy organizational, quality management,
resource and processes.
Good news: After the re-designation: process, the NB number will remain
the same / will NOT change!
Bad news: Some NBs will not be around and only selected few will have
a scope for Class III high-risk devices (alias SNB).

Conformity Assessment
Specific Procedure [Annex IX Section 5)
Applies to Class III implants and Class IIb active devices intended to
administer and/or remove a medicinal product

Conformity Assessment
Specific Procedure [Annex IX Section 5)
Applies to all Class III and Class IIb active devices intended to
administer and/or remove a medicinal product:
- Medical Device Expert Panel - clinical evaluation assessment report
- Adds to approval timeline (min. 60 days- max ???)
- Specific Procedure is not required for:

• Modified Devices from same manufacturer and differences accepted
by NB to not adversely affect the established risk/benefit ratio.
• Devices complying to devised CS (set out by Commission & MDCG)
• Renewals of Certificates.

Key Impacts
üNew Regulatory Requirements
üPre-Market Clinical Data Requirements
üPost-Market Reporting Requirements
üUDI & Distribution Channels
üQM System and Manufacturing
üChanging Notified Body Role

MDR- Preparing to Implement
Be informed, be prepared, identify opportunities and

implement in time …
• Assess your device portfolio
• Impact Assessment and Gap Analysis
• Portfolio/ Product Pipeline analysis for challenges and opportunities
MDR Implementation Plan

- Dossiers, clinical evaluation, PMCF & PMS integration
- System approaches, QMS, contracts, supplier control, RA knowledge
- Resource management (internal/external) including NB commitment / selection
- MDR Master Plan what needs to be done and when according to the MDR
implementation timeline

MDR- Preparing to Implement
Be informed, be proactive, identify opportunities and

implement in time …
• Communicate Master Plan with your Notified Body
• Plan for Contingencies and Delays
• Execution of Implementation
• Internal Monitoring / Internal audits
• Carefully Plan MDR Conformity Assessment with Notified Body

Thank You!

MDR Namsa Slides

Uploaded by

Copyright:

Available Formats

MDR Namsa Slides

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

MDR Namsa Slides

Uploaded by

Copyright:

Available Formats

What are the major changes introduced by the new MDR?

What are the major changes introduced by the new MDR?

What are the new key decision-making players under the MDR?

What are the new key decision-making players under the MDR?

MEDICAL RESEARCH ORGANIZATION

NAMSA The New European MDR| Confidential | 2

Key • Introduction to MDR

NAMSA The New European MDR| Confidential | 3

3 Year Transition 5 Year MDD

Q2/ 2017 2024

NAMSA The New European MDR| Confidential | 4

D=Directive: Legislation that R=Regulation: Mandatory

• Fundamental revision of existing MDD and AIMD

NAMSA The New European MDR| Confidential | 6

• Promote the global convergence of regulations.

Establish a robust, transparent, predictable and sustainable

NAMSA The New European MDR| Confidential | 7

• European Commission (EC)

NAMSA The New European MDR| Confidential | 8

NAMSA The New European MDR| Confidential | 9

NAMSA The New European MDR| Confidential | 10

• Software is considered an active medical device [Article 2

NAMSA The New European MDR| Confidential | 11

If decisions have an impact that may directly or

• Class III-­ the death or an irreversible deterioration of

NAMSA The New European MDR| Confidential | 12

NAMSA The New European MDR| Confidential | 13

• Introduced concept of Interoperability to devices including

NAMSA The New European MDR| Confidential | 14

NAMSA The New European MDR| Confidential | 15

• New and different reporting requirements

NAMSA The New European MDR| Confidential | 16

-­ Post-­Market Surveillance (PMS) Plan.

NAMSA The New European MDR| Confidential | 17

New centralized databases (EUDAMED):

NAMSA The New European MDR| Confidential | 18

Increase powers of the Competent Authorities to ensure swift

NAMSA The New European MDR| Confidential | 19

-­ Cooperation between CA and European Medicines

NAMSA The New European MDR| Confidential | 20

Greater emphasis and detailed QMS responsibilities.

NAMSA The New European MDR| Confidential | 21

• UDI system (Unique Device Identification System) to enable global

NAMSA The New European MDR| Confidential | 22

• UDI system (Unique Device Identification System) to enable

NAMSA The New European MDR| Confidential | 23

• UDI system (Unique Device Identification System) to enable

NAMSA The New European MDR| Confidential | 24

UDI Implementation Timelines by Manufacturers:

NAMSA The New European MDR| Confidential | 25

New understanding of Clinical Evaluation:

NAMSA The New European MDR| Confidential | 26

þ Only be based on a single CE-­Marked Device

þ Equivalency based on all three (3) design characteristics

þ No clinically significant difference in performance and safety

þ All differences need to be disclosed and critically evaluated

þ Notified Bodies may challenge equivalent device selection

Demonstration of Equivalency must be endorsed by the Notified

• Class III- the death or an irreversible deterioration of

- Post-Market Surveillance (PMS) Plan.

- Cooperation between CA and European Medicines

þ Only be based on a single CE-Marked Device

- Specific Procedure is not required for:

üPre-Market Clinical Data Requirements

üPost-Market Reporting Requirements